CSLLY:OTO-CSL Ltd ADR (Sponsored) (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 89.5

Change

-2.01 (-2.20)%

Market Cap

USD 42.04B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CSL Ltd is a biopharmaceutical company. It is engaged in research, development, manufacture, marketing and distribution of biopharmaceutical and related products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 5.92B

ETFs Containing CSLLY

FLDM:CA 2.04 % 0.44 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.89% 51% F 36% F
Dividend Return 0.61% 80% B- 14% F
Total Return -7.28% 52% F 36% F
Trailing 12 Months  
Capital Gain -11.29% 69% C- 52% F
Dividend Return 1.23% 38% F 14% F
Total Return -10.06% 69% C- 51% F
Trailing 5 Years  
Capital Gain 29.34% 85% B 76% C+
Dividend Return 7.27% 55% F 24% F
Total Return 36.60% 85% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 2.58% 49% F 44% F
Dividend Return 3.57% 50% F 42% F
Total Return 0.98% 42% F 23% F
Risk Return Profile  
Volatility (Standard Deviation) 15.56% 99% N/A 92% A
Risk Adjusted Return 22.92% 72% C 58% F
Market Capitalization 42.04B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.